Cryopreserved Platelet (CPP) Development for U.S. Food and Drug Administration Licensure

Background
The solicitation W81XWH19R0033 is being amended to address questions from potential Offerors regarding the Cryopreserved Platelet (CPP) Development for U.S. Food and Drug Administration Licensure. The U.S. Food and Drug Administration (FDA) is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices. The goal of this contract is to develop cryopreserved platelets for FDA licensure, which aligns with the FDA's mission of promoting and protecting public health.

Work Details
The contract involves the development of cryopreserved platelets for FDA licensure. The specific tasks include research, testing, and documentation related to the cryopreservation process, as well as meeting the regulatory requirements set forth by the FDA for licensure. Offerors will need to demonstrate expertise in cryopreservation techniques, quality control measures, and compliance with FDA regulations.